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A patient can present with a raised hemoglobin (Hb), raised white cell count (WCC) or leukocytosis, or raised platelet counts and in each case the causes of the abnormality have to be considered and investigated in order to arrive at the diagnosis. Each type of abnormality will be discussed and illustrative cases given. Cases presenting with simultaneous multiple raised cell counts will also be considered.
Erythrocytosis
An absolute or true erythrocytosis is present when the red cell mass is greater than 125% predicted for the patient's sex and body mass. Th e presence of an erythrocytosis is indicted by an Hb and/or a hematocrit (Hct ) above the upper limit of normal. However, a raised Hb or Hct may not necessarily indicate that a true erythrocytosis is present. It may be necessary to formally measure the red cell mass in order to prove that there is a true erythrocytosis as opposed to an apparent erythrocytosis (where the Hct is raised but the red cell mass is within the reference range) or a relative erythrocytosis (where the Hct is raised but the red cell mass is within the reference range and the plasma volume reduced). In cases where the Hct is above 0.60% in a male or 0.56% in a woman the red cell mass is always elevated and formal measurement of the red cell mass is unnecessary to prove the point. 1 
Diff erential diagnosis of erythrocytosis
An erythrocytosis can be primary where there is an intrinsic defect within the bone marrow compartment or secondary where something usually mediated by erythropoietin (EPO) is driving the red cell mass expansion. In each case the cause can be congenital or acquired. 
Initial assessment of an undiagnosed patient with erythrocytosis
Th e patient should be seen and the full blood picture (FBP) repeated to confi rm that the abnormality is present. A careful history and examination should then be carried out considering the diff erential diagnosis. 3 Having confi rmed the erythrocytosis if a diagnosis of polycythemia vera (PV) seems a possibility, the next investigation indicated is a test for JAK 2 mutations which, if positive, will confi rm clonal disease. 4 If PV does not seem likely then the next step would be to measure the EPO level. A low-level EPO suggests a primary defect in the EPO signaling pathway and this should then be investigated further. A normal or elevated EPO level suggests a secondary cause of erythrocytosis and this should then be investigated further, pursuing any suggestions from the history and examination. Figure 1 .1 is an algorithm of the suggested investigative route for a patient with erythrocytosis.
Case 1
An 18-year-old woman presented to the maternity unit 10 
Leukocytosis
A leukocytosis indicated by a raised WCC above the normal range can be due to raised neutrophils, eosinophils, or basophils. Th e diff erential WCC will reveal the type of leukocytosis and fully elucidate the type of elevated white cells. A monocytosis or lymphocytosis as the cause of the elevated WCC will be revealed and eliminated. White cells are produced and turned over in a very short time frame and a leukocytosis can develop and disappear very rapidly.
Diff erential diagnosis of a leukocytosis
Th e causes of a leukocytosis are extensive. A neutrophil leukocytosis can be due to any bacterial infection, particularly pyogenic infections, which will only be sustained if the infection continues. Neutrophilia is also part of the response to any infl ammation or tissue 
4
damage, acute hemorrhage or hemolysis. Any neoplasm can be associated with neutrophilia. Many drugs such as corticosteroids can cause neutrophilia and it is the desired response from administration of granulocyte colony-stimulating factor. Myeloproliferative neoplasms, both Philadelphia -positive and -negative, frequently have an associated neutrophilia. 6 Other causes include chronic smoking and asplenia.
An eosinophil leukocytosis has many potential causes, including allergic and parasitic disorders, any metastatic malignancy, systemic disorders such as polyarteritis nodosa , many skin diseases, and vasculitis . Hematological causes include Hodgkin's disease , many of the myeloproliferative neoplasms, and graft -versus-host disease . Th ere are also a number of specifi c hypereosinophilic syndromes and pulmonary syndromes which cause eosinophilia.
A basophil leukocytosis is rare but can be caused by viral infections such as smallpox and chickenpox, myxoedema, ulcerative colitis, and in myeloproliferative neoplasms.
A summary list of causes of leukocytosis is presented in Table 1 .1 .
Initial assessment of an undiagnosed patient with leukocytosis
Th e patient with a leukocytosis should be seen and have the blood test repeated to confi rm that the abnormality remains present. Th e patient should have a careful history taken, including lifestyle issues and examination carried out with consideration of the diff erential diagnosis. Th e diff erential WCC will give information on the type of leukocyte involved. A blood fi lm needs to be examined. Further investigation then depends upon the information at this point. Any likely cause needs to be further investigated. Molecular testing looking for a clonal disorder ( BCR/ABL , JAK 2 , MPL , and CALR ) should be undertaken if there is no obvious cause, to look for a myeloproliferative neoplasm; specifi c tests such as CSF3R mutations may be considered. 
Thrombocytosis
A thrombocytosis is present when the platelet count is raised above the normal range, greater than 450 × 10 9 /L. A markedly and repeatedly raised thrombocytosis is of importance, but the signifi cance of one just above the normal range is diffi cult to assess.
Diff erential diagnosis of a thrombocytosis
A raised platelet count can be due to a primary defect in the bone marrow or primary thrombocytosis, or a secondary thrombocytosis where something else drives the increase in the platelet count. Th ere are also a number of reasons where something else may be counted as platelets, erroneously leading to spuriously raised platelets. Bone marrow disorders which lead to primary thrombocytosis include essential thrombocythemia , where there is an acquired clone in the bone marrow driving the platelet production. Th e identifi ed clones include JAK 2 , MPL , 9 and, more recently CALR , 10 , 11 although there are still cases where no clone has yet been identifi ed. Other myeloproliferative neoplasms, both Philadelphia-positive and -negative, and myelodysplastic syndromes can present with thrombocytosis which is primary. Th ere are many secondary causes for thrombocytosis where increased platelets are produced as part of the reaction to the underlying disorder. Th is includes response to infection, any infl ammation or tissue damage, iron-defi ciency hemorrhage and hemolysis, and malignancy. Various cellular elements can be counted as platelets by analyzers. Bacteria, schistocytes, and Pappenheimer bodies , for instance, can be counted, and lead to a spurious platelet reading.
12 Th e causes of thrombocytosis are listed in Table 1 .1 .
Initial assessment of an undiagnosed patient with thrombocytosis
As with other patients with an elevated count, the initial assessment is to repeat the count and confi rm that there is actually a sustained elevation of the platelet count. Th e patient then needs to be reviewed and assessed with a careful history and examination. Attention to a search for secondary reactive causes should be included. Th e next step is to review the blood fi lm and test the iron status (ferritin ) and for acute-phase reactants C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). An elevated acute-phase reactant suggests a reactive thrombocytosis. Iron defi ciency should be treated to see if the platelet count decreases. If it does not fall into either of these categories and the elevated platelet count is sustained on repeat, then molecular testing should be carried out, looking for an acquired clone and bone marrow aspirate; trephine and cytogenetic testing should be considered. Th e algorithm in Figure 1 .3 sets out the diagnostic pathway.
Case 6
A Initial assessment of an undiagnosed patient more than one cell line elevated
Th is article has concentrated on the elevation of single cell lines and the diagnostic pathway for each. However, many patients present with elevation of more than one cell line. Th ey need to be investigated in a similar manner with repetition of the blood count to confi rm the abnormality and examination of the blood fi lm. Careful history taking and examination are required, looking for reactive and primary or secondary causes, testing to eliminate reactive causes, and then bone marrow and molecular testing for hematological disorders. Th e cases which follow illustrate where the patient presents with more than one cell lineage elevated.
Case 9
Th 
Summary
Patients presenting with an elevated blood count need it to be repeated aft er a period of time to confi rm the abnormality. Th e patient then needs a thorough history and examination considering primary and secondary causes of the abnormality. A blood fi lm should be examined and then further investigation follows a pathway depending on initial results. Bone marrow examination and molecular testing may reveal the hematological diagnosis.
Introduction
Chronic myeloproliferative neoplasms (MPN) comprise diverse disorders, some with proliferative features and others with dysplastic hematopoiesis. In an attempt to improve their classifi cation, the World Health Organization (WHO) has divided them into three principal categories: (1) MPN ; (2) myelodysplastic syndrome/MPN (MDS/MPN) ; and (3) myeloid and lymphoid neoplasms with eosinophilia (MLN-eo) and abnormalities of PDGFRA , PDGFRB , or FGFR1 . 1 Th e MPN category includes four predominant subtypes: chronic myeloid leukemia plus the three so-called "classical" BCR-ABL1 -negative disorders polycythemia vera, primary myelofi brosis, and essential thrombocythemia. In addition, this category also includes the rarer "atypical" entities mastocytosis , chronic eosinophilic leukemia (CEL) , chronic neutrophilic leukemia (CNL) , and MPN-unclassifi able. Th e MDS/MPN category comprises chronic myelomonocytic leukemia (CMML) , juvenile myelomonocytic leukemia (JMML) , atypical chronic myeloid leukemia (aCML) , a "provisional entity, " refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) , and a "by exclusion" subcategory, MDS/MPN-unclassifi able (MDS/MPN-U). 1 Th is review focuses on the molecular diagnosis of atypical MPN, MLN-eo, and MDS/MPN subtypes, many of which are diffi cult to distinguish in routine practice.
Mast cell disease

Pathogenesis and classifi cation
Mastocytosis is a rare and heterogeneous disease that is characterized by the accumulation of abnormal mast cells in one or more tissues, predominantly skin, bone marrow (BM) and visceral organs, resulting in organ dysfunction in severe cases. It can aff ect children and adults, but the disease characteristics are very diff erent between diff erent subtypes and the WHO therefore distinguishes several distinct variants of cutaneous mastocytosis (CM) and systemic mastocytosis (SM).
Th e extent of organ infi ltration and subsequent organ damage is the basis for the classifi cation of SM into indolent SM (ISM), SM with associated clonal hematologic non-mast cell lineage disease (SM-AHNMD), aggressive SM (ASM), and mast cell leukemia (MCL). In patients with SM-AHNMD, the SM component can resemble ISM, ASM, or even MCL. Depending on the subtype of SM, cell source (BM or peripheral blood, PB) and assay sensitivity, an acquired mutation in the KIT gene (usually resulting in a D816V amino acid substitution) is detectable in more than 80-90% of adult cases. Th e proto-oncogene KIT encodes a receptor tyrosine kinase (KIT; also known as CD117) whose ligand is stem cell factor (SCF). SCF/KIT signaling is important for the control of mast cell development/proliferation and the KIT mutations seen in mastocytosis result in 10 constitutive receptor activation in the absence of SCF. Consequently KIT mutations are believed to be the direct driver of aberrant mast cell proliferation, although additional mutations contribute to the precise phenotype and severity of the disease. 2 , 3 Childhood-onset mastocytosis is also a heterogeneous group of disorders. Most cases present during the fi rst year of life and, although not generally considered a hereditary disease, familial cases have been described. 4 Th e course of mastocytosis varies substantially and is infl uenced by the subtype and the age of onset. Most children have a form of CM, such as urticaria pigmentosa (UP) , mastocytoma of the skin, or diff use CM and the disease usually remains confi ned to the skin. Lymphadenopathy, hepatomegaly, or splenomegaly is only rarely seen in children with mastocytosis and in most cases blood cell counts and serum chemistry parameters are normal. 5 Th e simplest marker for the diagnosis and severity of mastocytosis is serum tryptase . Tryptases are proteases located in mast cell granules and the median tryptase level in the healthy population is 5 ng/mL. In CM the levels are roughly double that found in healthy individuals but are oft en much higher, e.g., 50-100 ng/ mL or more in SM and as high as >1,000 ng/mL in ASM and MCL. Although a BM investigation is performed routinely in adults with mastocytosis, 6 this is not generally undertaken for children unless the serum tryptase level increases over time, the level is massively elevated, or there are other clinical or laboratory signs of systemic disease. A skin biopsy is desirable to confi rm the clinical diagnosis of CM, although observation alone may be appropriate in very young children. Th e histological appearances of the clinical variants of UP are similar; the diff erences depend on the degree of mast cell infi ltration. Th e mast cells are round or spindle-shaped with abundant eosinophilic cytoplasm and eosinophils are oft en present.
Although children with mastocytosis generally follow a benign self-limited course with improvement or resolution and no progression to systemic disease, mastocytosis is nevertheless a clonal disease most commonly associated with D816V and other activating KIT mutations. In a large cohort of pediatric patients where the entire KIT sequence was analyzed in DNA extracted from skin biopsies, the D816V mutation was found in 42% of cases and mutations in other exons were observed in 44%. 7 It thus appears that the large majority of pediatric patients have alterations in KIT , supporting the idea that childhood mastocytosis is also a clonal disease but with a broader spectrum of KIT mutations than seen in adults. Although important for the diagnosis of adult cases, knowing the KIT mutational status of most children is not currently considered to be of great importance for most children in routine clinical practice. 8 
Diagnostic procedures
Th e abnormal clone in mastocytosis is oft en highly focal in skin lesions or the BM, and is either absent or present at very low levels in PB. Consequently relevant mutations are harder to detect compared to other myeloid neoplasms and it is essential to use a mutation assay with high sensitivity, or to purify mast cells by fl ow cytometry or laser microdissection.
Conventional Sanger sequencing has a sensitivity of mutation detection of about 20% and thus can only be used on purifi ed mast cells or skin biopsies with high levels of mast cell infi ltration. For analysis of BM or PB, it is essential to use an assay with a sensitivity of detection of 0.1-1%. Several such techniques have been developed, as reviewed elsewhere, 8 but most centers currently employ quantitative polymerase chain reaction -based techniques to detect KIT D816V in genomic DNA or RNA/cDNA. 9 , 10 For many patients the level of disease, as assessed by the mutational burden, is signifi cantly higher in the BM compared to the PB and consequently BM is the preferred tissue for mutational analysis. It is perfectly acceptable, however, to perform an initial mutation screen on a PB sample and then consider further analysis of the BM if the result is negative. If the BM tests negative for D816V and there is strong evidence for a diagnosis of SM, then Sanger sequencing or next-generation sequencing (assay sensitivity typically 1-5%) of KIT exon 17 should be considered to detect rare activating KIT variants, the most common of which are D816Y and D816H. Due to the complexity of the analysis most centers do not report mutation levels, but emerging evidence indicates that the multilineage involvement of KIT D816V and the KIT D816V allele burden have an important impact on disease phenotype and prognosis. 2 , 10 As indicated above, KIT mutation analysis is not considered to be warranted in children in the absence of indicators of systemic disease. Nevertheless, KIT mutations are detectable in exons 8, 9, 11, or 17 in most cases by Sanger sequencing of DNA extracted from cutaneous biopsies. 7 Further work is required to determine the clinical signifi cance of these mutations.
